Literature DB >> 16985977

Prostate cancer update: advanced disease.

Michael A Carducci.   

Abstract

The presentations for the "Advanced Disease" section of the 13th International Prostate Cancer Update provided an overview of current and future directions in the management of men with recurrent prostate cancer after local therapy and those with metastatic disease. Definitions of biochemical failure after local therapy were reviewed. Treatment strategies that were discussed included salvage radiation, early/intermittent hormonal therapy, cytotoxic chemotherapy, the use of bisphosphonates, and gene therapy. Several possible molecular targets for prostate cancer treatment need further validation before testing in clinical trials, and examples of these were presented. Each presentation focused on the need to accrue men to clinical trials to enable progress at a faster pace.

Entities:  

Year:  2003        PMID: 16985977      PMCID: PMC1502374     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  17 in total

Review 1.  Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors.

Authors:  S D Gore; M A Carducci
Journal:  Expert Opin Investig Drugs       Date:  2000-12       Impact factor: 6.206

Review 2.  Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis.

Authors:  G J van Leenders; J A Schalken
Journal:  BJU Int       Date:  2001-09       Impact factor: 5.588

Review 3.  Timing hormonal therapy in prostate cancer.

Authors:  Annette E Sessions; Edward M Messing
Journal:  Urol Clin North Am       Date:  2002-02       Impact factor: 2.241

4.  Proposed substages for metastatic prostate cancer.

Authors:  E D Crawford; B A Blumenstein
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

5.  Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.

Authors:  T M Beer; W C Pierce; B A Lowe; W D Henner
Journal:  Ann Oncol       Date:  2001-09       Impact factor: 32.976

Review 6.  Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.

Authors:  Celestia S Higano
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

7.  Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.

Authors:  C Trivedi; B Redman; L E Flaherty; O Kucuk; W Du; L K Heilbrun; M Hussain
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

8.  Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

Authors:  D M Savarese; S Halabi; V Hars; W L Akerley; M E Taplin; P A Godley; A Hussain; E J Small; N J Vogelzang
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

9.  Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.

Authors:  J Picus; M Schultz
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

10.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.